332 related articles for article (PubMed ID: 8762149)
41. Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes.
Krishnan R; Zhang E; Hakansson K; Arni RK; Tulinsky A; Lim-Wilby MS; Levy OE; Semple JE; Brunck TK
Biochemistry; 1998 Sep; 37(35):12094-103. PubMed ID: 9724521
[TBL] [Abstract][Full Text] [Related]
42. Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin.
Rehse PH; Steinmetzer T; Li Y; Konishi Y; Cygler M
Biochemistry; 1995 Sep; 34(36):11537-44. PubMed ID: 7547884
[TBL] [Abstract][Full Text] [Related]
43. Binding affinities for sulfonamide inhibitors with human thrombin using Monte Carlo simulations with a linear response method.
Jones-Hertzog DK; Jorgensen WL
J Med Chem; 1997 May; 40(10):1539-49. PubMed ID: 9154975
[TBL] [Abstract][Full Text] [Related]
44. Compounds binding to the S2-S3 pockets of thrombin.
Nilsson M; Hämäläinen M; Ivarsson M; Gottfries J; Xue Y; Hansson S; Isaksson R; Fex T
J Med Chem; 2009 May; 52(9):2708-15. PubMed ID: 19371038
[TBL] [Abstract][Full Text] [Related]
45. Study of the Differential Activity of Thrombin Inhibitors Using Docking, QSAR, Molecular Dynamics, and MM-GBSA.
Mena-Ulecia K; Tiznado W; Caballero J
PLoS One; 2015; 10(11):e0142774. PubMed ID: 26599107
[TBL] [Abstract][Full Text] [Related]
46. Structure of the Ser195Ala mutant of human alpha--thrombin complexed with fibrinopeptide A(7--16): evidence for residual catalytic activity.
Krishnan R; Sadler JE; Tulinsky A
Acta Crystallogr D Biol Crystallogr; 2000 Apr; 56(Pt 4):406-10. PubMed ID: 10739913
[TBL] [Abstract][Full Text] [Related]
47. Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090.
Malley MF; Tabernero L; Chang CY; Ohringer SL; Roberts DG; Das J; Sack JS
Protein Sci; 1996 Feb; 5(2):221-8. PubMed ID: 8745399
[TBL] [Abstract][Full Text] [Related]
48. The structure of a designed peptidomimetic inhibitor complex of alpha-thrombin.
Wu TP; Yee V; Tulinsky A; Chrusciel RA; Nakanishi H; Shen R; Priebe C; Kahn M
Protein Eng; 1993 Jul; 6(5):471-8. PubMed ID: 8415574
[TBL] [Abstract][Full Text] [Related]
49. Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design.
Engh RA; Brandstetter H; Sucher G; Eichinger A; Baumann U; Bode W; Huber R; Poll T; Rudolph R; von der Saal W
Structure; 1996 Nov; 4(11):1353-62. PubMed ID: 8939759
[TBL] [Abstract][Full Text] [Related]
50. Allosteric changes in solvent accessibility observed in thrombin upon active site occupation.
Croy CH; Koeppe JR; Bergqvist S; Komives EA
Biochemistry; 2004 May; 43(18):5246-55. PubMed ID: 15122890
[TBL] [Abstract][Full Text] [Related]
51. Electrostatic steering and ionic tethering in the formation of thrombin-hirudin complexes: the role of the thrombin anion-binding exosite-I.
Myles T; Le Bonniec BF; Betz A; Stone SR
Biochemistry; 2001 Apr; 40(16):4972-9. PubMed ID: 11305913
[TBL] [Abstract][Full Text] [Related]
52. Effect of Thrombin Inhibitors on Positive Feedback in the Coagulation Cascade.
Ustinov NB; Zav'yalova EG; Kopylov AM
Biochemistry (Mosc); 2016 Mar; 81(3):242-8. PubMed ID: 27262193
[TBL] [Abstract][Full Text] [Related]
53. Structure of human des(1-45) factor Xa at 2.2 A resolution.
Padmanabhan K; Padmanabhan KP; Tulinsky A; Park CH; Bode W; Huber R; Blankenship DT; Cardin AD; Kisiel W
J Mol Biol; 1993 Aug; 232(3):947-66. PubMed ID: 8355279
[TBL] [Abstract][Full Text] [Related]
54. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond.
DiMaio J; Ni F; Gibbs B; Konishi Y
FEBS Lett; 1991 Apr; 282(1):47-52. PubMed ID: 2026264
[TBL] [Abstract][Full Text] [Related]
55. Proton bridging in the interactions of thrombin with hirudin and its mimics.
Kovach IM; Kakalis L; Jordan F; Zhang D
Biochemistry; 2013 Apr; 52(14):2472-81. PubMed ID: 23517305
[TBL] [Abstract][Full Text] [Related]
56. Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template.
Jhoti H; Cleasby A; Reid S; Thomas PJ; Weir M; Wonacott A
Biochemistry; 1999 Jun; 38(25):7969-77. PubMed ID: 10387040
[TBL] [Abstract][Full Text] [Related]
57. The X-ray crystal structure of thrombin in complex with N alpha-2-naphthylsulfonyl-L-3-amidino-phenylalanyl-4-methylpiperidide: the beneficial effect of filling out an empty cavity.
Bergner A; Bauer M; Brandstetter H; Stürzebecher J; Bode W
J Enzyme Inhib; 1995; 9(1):101-10. PubMed ID: 8568562
[TBL] [Abstract][Full Text] [Related]
58. Novel natural product 5,5-trans-lactone inhibitors of human alpha-thrombin: mechanism of action and structural studies.
Weir MP; Bethell SS; Cleasby A; Campbell CJ; Dennis RJ; Dix CJ; Finch H; Jhoti H; Mooney CJ; Patel S; Tang CM; Ward M; Wonacott AJ; Wharton CW
Biochemistry; 1998 May; 37(19):6645-57. PubMed ID: 9578548
[TBL] [Abstract][Full Text] [Related]
59. Allosteric changes of thrombin catalytic site induced by interaction of bothrojaracin with anion-binding exosites I and II.
Monteiro RQ; Rapôso JG; Wisner A; Guimarães JA; Bon C; Zingali RB
Biochem Biophys Res Commun; 1999 Sep; 262(3):819-22. PubMed ID: 10471408
[TBL] [Abstract][Full Text] [Related]
60. Molecular dynamics simulations of thrombin inhibitors at the S' subsites of thrombin.
Yue SY; Konishi Y
Drug Des Discov; 1994 Jul; 12(1):1-17. PubMed ID: 7578804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
